Biovica International
16.11.2021 09:38:17 CET | ACCESS Newswire | Press release
UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.
Care for metastatic breast cancer patients is a large burden on healthcare systems due to cost of therapies, cost of monitoring tests, and management of side effects. The results from this study show that adding DiviTumTKa to care could give a net reduction in costs of up to three times the spend on the new test. The savings come from a decrease in the usage of other monitoring tools such as CT scans and bone scans, and from shortening the amount of time a patient receives expensive medical treatments that ultimately prove to be ineffective.
"Our analysis showed that inclusion of DiviTum®TKa could reduce use of a substantial proportion of traditional monitoring. If use of DiviTum®TKa can also predict lack of benefit from costly CDK4/6i therapy and clinicians then act on that information in a timely fashion, our model suggests that this will result in substantial cost savings to patients and health plans," said Scott D. Ramsey from the Fred Hutchison Cancer Research Center.
"This analysis reinforces our belief that DiviTum®TKa will improve the lives of patients and reduce costs in healthcare. From discussions with patients, we also know that they prefer a regular blood test as a better option than current monitoring practices." said Anders Rylander, CEO of Biovica.
The study publication is included in the November 2021 issue of the Journal of Medical Economics https://doi.org/10.1080/13696998.2021.2003674
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Biovica's DiviTum®TKa results published in Journal of Medical Economics
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673068/Biovicas-DiviTumRTKa-Results-Published-in-Journal-of-Medical-Economics
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
Litum Brings High-Precision Location Visibility to Zone 1 and Zone 2 Hazardous Environments15.6.2026 09:00:00 CEST | Press release
Combining ATEX Zone 1 and Zone 2 suitability with high-precision location capability, the ATEX Gateway and ATEX Dualis Tag set a new benchmark for intrinsically safe RTLS in hazardous industrial environments BOSTON, MA / ACCESS Newswire / June 15, 2026 / Litum, a global leader in real-time location systems, today announced the ATEX Family: a purpose-built hardware suite comprising the ATEX Gateway and ATEX Dualis Tag. Compliant with both Zone 1 and Zone 2 hazardous areas, the ATEX Family is designed to deliver sub-meter location accuracy and better visibility in environments where standard connected devices cannot be safely deployed. The launch marks a significant step forward for industrial organizations that need to track critical assets, equipment, tools, materials, and people in environments where explosive gases, vapors, or combustible dust may be present. By combining intrinsically safe design with Ultra-Wideband (UWB) and Bluetooth Low Energy (BLE) location capability, Litum ena
GA-ASI and INTEC Group Sign MOU at ILA Berlin11.6.2026 17:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / June 11, 2026 / Today at the ILA Berlin Air Show, General Atomics Aeronautical Systems, Inc. (GA-ASI) and the INTEC Group signed a Memorandum of Understanding (MoU) for INTEC to support the architecture and integration of mission systems, entry into service and logistic support services for GA-ASI's Gambit Series of Collaborative Combat Aircraft (CCA). The work is intended to provide sovereign capabilities to meet the growing interest in CCA in Germany. The MoU was signed by GA-ASI CEO Linden Blue and INTEC Group CEO Christoph Otten. GA-ASI's flight-proven Gambit CCA provides a common platform for air-to-air, air-to-ground and electronic warfare missions. Gambit is an uncrewed combat jet optimized for attack roles such as electronic warfare, Suppression of Enemy Air Defenses (SEAD), Destruction of Enemy Air Defenses (DEAD) and stand-off precision strike, making it a versatile option for evolving security needs. GA-ASI is currently flight testing the YFQ-4
U.S. Polo Assn. Palm Beaches Marathon Celebrates America's 250th, Adds $17,000 in Prize Money as it Returns December 12-13, 202611.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 11, 2026 / The 2026 U.S. Polo Assn. Palm Beaches Marathon, a celebration of America's 250th, will introduce prize money for its top Marathon runners for the first time when the race returns to the streets of West Palm Beach on December 12-13, 2026, a move that will attract elite runners worldwide and elevate the status of Palm Beach County's most treasured road test. The introduction of $17,000 in prize money is the next strategic step for elevating this racing event that has experienced record growth in recent years. The men's and women's winners of the Marathon race will each receive $5,000, second-place finishers will receive $2,500, and third place will be worth $1,000. The winners' share of the purse is the largest in the state of Florida. In celebration of America's 250th, the 2026 U.S. Polo Assn. Palm Beaches Marathon Logo has been re-designed in stunning brushstrokes of red, white and blue to accompany the brand's iconic double horse
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom